Ticagrelor in patients with diabetes and stable coronary artery disease with a history of previous percutaneous coronary intervention (THEMIS-PCI): a phase 3, placebo-controlled, randomised trial

I pazienti con CAD stabile e diabete, che hanno subito una PCI, possono beneficiare dell'aggiunta di ticagrelor al trattamento con aspirina? (Lancet. 2019 Aug 30)

13 Settembre Set 2019 9 days ago
  • Assanelli E

Patients with stable coronary artery disease and diabetes with previous percutaneous coronary intervention (PCI), particularly those with previous stenting, are at high risk of ischaemic events. These patients are generally treated with aspirin.

In a large (11,154 patients enrolled) phase 3, placebo-controlled, multicentric (1315 sites in 42 countries) randomised trial. the Authoras aimed to investigate if these patients would benefit from treatment with aspirin plus ticagrelor.

The results show that long-term therapy with ticagrelor in addition to aspirin should be considered in patients with diabetes and a history of PCI who have tolerated antiplatelet therapy, have high ischaemic risk, and low bleeding risk.


Reference
1. Bhatt DL, Steg PG, Mehta SR, Leiter LA, Simon T, Fox K, Held C, Andersson M, Himmelmann A, Ridderstråle W, Chen J, Song Y, Diaz R, Goto S, James SK, Ray KK, Parkhomenko AN, Kosiborod MN, McGuire DK, Harrington RA; THEMIS Steering Committee and Investigators. Assanelli E among collaborators. Ticagrelor in patients with diabetes and stable coronary artery disease with a history of previous percutaneous coronary intervention (THEMIS-PCI): a phase 3, placebo-controlled, randomised trial. Lancet 2019 Aug 30. pii: S0140-6736(19)31887-2. doi: 10.1016/S0140-6736(19)31887-2 Go to PubMed